Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors, specifically found on Lipid II, is a critical molecular target in bacterial cell wall biosynthesis. Lipid II is an essential, low-abundance intermediate that carries the disaccharide-pentapeptide monomer across the cytoplasmic membrane to be polymerized and cross-linked into the mature peptidoglycan mesh. The terminal D-Ala-D-Ala dipeptide serves as the substrate for bacterial transpeptidases (penicillin-binding proteins), which catalyze the cross-linking of adjacent peptidoglycan strands to provide structural integrity and prevent osmotic lysis.
This pathway is highly conserved in Gram-positive bacteria, making the D-Ala-D-Ala terminus a prime target for glycopeptide and lipoglycopeptide antibiotics. Drugs such as vancomycin, teicoplanin, and dalbavancin bind with high affinity to this terminus via hydrogen bonding, sterically hindering the transpeptidation and transglycosylation steps. This disruption weakens the cell wall, leading to bacterial cell lysis and death. However, resistance can arise when bacteria modify this target, replacing the terminal D-Ala with D-lactate or D-serine, which drastically reduces drug binding affinity.
Inhibition of bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing transglycosylation and transpeptidation (cross-linking) of the peptidoglycan layer.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursors (D-Ala-D-Ala).